“This new round was really an insider round,” Medable co-founder and CEO Michelle Longmire, M.D., told Crunchbase News. “We were not really raising money, but they saw the continued growth we were having and wanted to have another bite of the apple. It gives us wind in our sails to optimize at our full commercial potential.”
The Palo Alto-based company’s digital platform streamlines design, recruitment, retention and data quality for decentralized clinical trials, so patients, sites and clinical trial teams are better connected and patient access, experience and outcomes are improved.
“When we met Medable, the team, product and mission stood out immediately,” said Tina
Hoang-To, partner at Obvious Ventures, in a statement. “Unlike competitors that have built technology for a single part of the value chain, Medable addresses every part of the clinical trial tech stack from patient recruitment to virtual visits to outcomes assessment — enabling customers to run trials anytime anywhere on a single platform.”
The new investment brings Medable’s total funding to $217 million, Longmire said. This includes both the Series C and a $25 million round raised last May. She did not disclose the company’s new valuation, but did reveal that it “was a significant step-up from two months ago.”
Since its initial Series C round last November, Medable experienced strong commercial growth of 400 percent in revenue driven by the COVID-19 pandemic and demand for remote clinical trial technologies. It also launched five new products and onboarded more than 50 new clients and saw more than 90 percent retention rate among customers during the year.
“We see this growth continuing on the same trajectory, and compared to all of the tech categories, we were almost an outlier in terms of growth,” Longmire said.